{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:55Z","timestamp":1787026495661,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870026"],"award-info":[{"award-number":["81870026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinically, only a minority of patients benefit from immunotherapy and few efficient biomarkers have been identified to distinguish patients who would respond to immunotherapy. The tumor microenvironment (TME) is reported to contribute to immunotherapy response, but details remain unknown. We aimed to construct a prognostic model based on the TME of lung adenocarcinoma (LUAD) to predict the prognosis and immunotherapy efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated computational algorithms to describe the immune infiltrative landscape of LUAD patients. With the least absolute shrinkage and selection operator (LASSO) and Cox regression analyses, we developed a LUAD tumor microenvironment prognostic signature (LATPS). Subsequently, the immune characteristics and the benefit of immunotherapy in LATPS-defined subgroups were analyzed. RNA sequencing of tumor samples from 28 lung cancer patients treated with anti-PD-1 therapy was conducted to verify the predictive value of the LATPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We constructed the LATPS grounded on four genes, including UBE2T, KRT6A, IRX2, and CD3D. The LATPS-low subgroup had a better overall survival (OS) and tended to have a hot immune phenotype, which was characterized by an elevated abundance of immune cell infiltration and increased activity of immune-related pathways. Additionally, tumor immune dysfunction and exclusion (TIDE) score was markedly decreased in the LATPS-low subgroup, indicating an enhanced opportunity to benefit from immunotherapy. Survival analysis in 28 advanced lung cancer patients treated with an anti-PD-1 regimen at Nanfang hospital revealed that the LATPS-low subgroup had better immunotherapy benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LATPS is an effective predictor to distinguish survival, immune characteristics, and immunotherapy benefit in LUAD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1064874","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:02:54Z","timestamp":1669309374000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response"],"prefix":"10.3389","volume":"13","author":[{"given":"Jihong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunna","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12789","article-title":"Immunotherapy for lung cancer","volume":"21","author":"Steven","year":"2016","journal-title":"Respirology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-Small-Cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-020-01170-0","article-title":"M 6 a regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts356","article-title":"RSeQC: quality control of RNA-seq experiments","volume":"28","author":"Wang","year":"2012","journal-title":"Bioinformatics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat Methods"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an r package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for cox's proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000491","article-title":"Lung metastases share common immune features regardless of primary tumor origin","volume":"8","author":"Garc\u00eda-Mulero","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.182416","article-title":"Biostatistics series module 3: Comparing groups: Numerical variables","volume":"61","author":"Hazra","year":"2016","journal-title":"Indian J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01853-y","article-title":"A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma","volume":"40","author":"Wu","year":"2021","journal-title":"Oncogene"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8128","article-title":"Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma","volume":"7","author":"Yue","year":"2019","journal-title":"PeerJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1 + CD8 + T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70155-3","article-title":"Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy","volume":"13","author":"Jacobs","year":"2012","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1825-6","article-title":"Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation","volume":"65","author":"Ke","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2166","article-title":"An immune-related gene prognostic index for head and neck squamous cell carcinoma","volume":"27","author":"Chen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02817-z","article-title":"Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma","volume":"70","author":"Yi","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8 + T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03147-4","article-title":"Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics","volume":"146","author":"Guo","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S320393","article-title":"The relationship between UBE2C and AGGF1 overexpression and tumor angiogenesis in non-small cell lung cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.694071","article-title":"KRT6A promotes lung cancer cell growth and invasion through MYC-regulated pentose phosphate pathway","volume":"9","author":"Che","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B39","article-title":"Up-regulation of the IRX2 gene predicts poor prognosis in nasopharyngeal carcinoma","volume":"11","author":"Si","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/imt-2019-0145","article-title":"CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer","volume":"12","author":"Yang","year":"2020","journal-title":"Immunotherapy"},{"key":"B41","doi-asserted-by":"publisher","first-page":":BSR20202898","DOI":"10.1042\/BSR20202898","article-title":"Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment","volume":"41","author":"Zhu","year":"2021","journal-title":"Biosci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9960905","article-title":"Identification of CD8+ T cell-related genes: Correlations with immune phenotypes and outcomes of liver cancer","volume":"2021","author":"Pan","year":"2021","journal-title":"J Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1158\/2326-6066.CIR-13-0078","article-title":"Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer","volume":"1","author":"Brahmer","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.223","article-title":"Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets","volume":"13","author":"Smit","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.672904","article-title":"Ferroptosis-related genes in lung adenocarcinoma: Prognostic signature and immune, drug resistance, mutation analysis","volume":"12","author":"Ren","year":"2021","journal-title":"Front Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.665276","article-title":"Identification of prognostic signature and gliclazide as candidate drugs in lung adenocarcinoma","volume":"11","author":"Cheng","year":"2021","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1064874\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:02:59Z","timestamp":1669309379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1064874\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.1064874"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1064874","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"1064874"}}